Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies, Inc. filings document the regulatory record of a public medical aesthetics company that provides premium body contouring procedures. Its 8-K reports cover operating and financial results, preliminary updates, non-GAAP financial measures, reconciliations, debt and capital-structure disclosures, material agreements, and governance events.
Proxy materials describe annual meeting matters, director elections, shareholder voting items, board structure, and related governance disclosures. Other filings include late-filing notices tied to annual report timing, amendments correcting non-GAAP presentation, and emerging growth company status under SEC reporting rules.
AirSculpt Technologies, Inc. held its 2026 annual stockholder meeting virtually on May 12, 2026. A total of 65,895,278 shares of Class A common stock were present or represented by proxy, which was 93.49% of the 70,486,528 shares entitled to vote as of March 13, 2026.
Stockholders elected three Class II directors—Adam Feinstein, Thomas Aaron, and Kenneth Higgins—to serve until the 2029 annual meeting. Each nominee received more than 33.8 million votes "for," with broker non-votes reported on this proposal.
Stockholders also ratified the selection of Grant Thornton LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026, with 41,551,299 votes for, 24,343,978 against, and 1 abstention. No other matters were submitted for a vote.
AirSculpt Technologies, Inc. reported essentially flat performance for the three months ended March 31, 2026, generating revenue of $39.4 million on 3,082 cases, similar to $39.4 million and 3,076 cases a year earlier. Revenue per case was stable at about $12,780.
The company posted a net loss of $2.4 million, modestly better than the $2.8 million loss in 2025, while Adjusted EBITDA declined to $3.3 million, an 8.4% margin versus 9.5% a year ago, reflecting higher selling, general and administrative costs.
AirSculpt strengthened its balance sheet by raising approximately $14.6 million through its at-the-market equity program and voluntarily prepaying $10.0 million on its term loan, reducing total debt, net, to $44.8 million. Cash and cash equivalents increased to $16.7 million, and management concluded there is no substantial doubt about the company’s ability to continue as a going concern. However, previously disclosed material weaknesses in internal control over financial reporting, including general accounting processes and lease accounting under ASC 842, remained unremediated as of March 31, 2026.
AirSculpt Technologies reported first-quarter 2026 results with stable revenue and a smaller loss. Revenue was $39.4 million, essentially flat with the prior-year quarter, while case volume edged up to 3,082 and same-center sales increased 1%.
Net loss improved to $2.4 million from $2.8 million, and Adjusted EBITDA declined to $3.3 million from $3.8 million, with an Adjusted EBITDA margin of 8.4%. The company reaffirmed full-year 2026 guidance for revenue of approximately $151 to $157 million and Adjusted EBITDA of approximately $15 to $17 million. Cash and cash equivalents rose to $16.7 million as of March 31, 2026, aided by $14.6 million raised under an at-the-market equity program and $11.4 million of debt repayment, reducing long-term debt while maintaining compliance with all covenants.
Airsculpt Technologies, Inc. amendment reports Parian Ultreia beneficially owns 6,744,000 shares (9.6%). The Schedule 13G/A (Amendment No. 2) lists Parian Ultreia as a Delaware filer holding 6,744,000 shares with sole voting and dispositive power. The filing is signed by Portfolio Manager Zachary Miller and dated 04/21/2026.
Airsculpt Technologies, Inc. insider Jorey Chernett reported an open-market purchase of 40,000 shares of Common Stock at a weighted average price of $2.54 per share. After this transaction, Chernett directly owns 7,053,761 Common Stock shares. The filing notes the shares were bought in multiple trades between $2.52 and $2.56.
The filing also reports the expiration of short call option positions on Airsculpt common stock. Call options on 200,000 underlying shares with a $5.00 exercise price and on 200,400 underlying shares with a $4.00 exercise price expired unexercised because the market price was below the exercise prices, and no consideration was received in connection with these expirations.
AirSculpt Technologies, Inc. is holding a virtual annual stockholder meeting on May 12, 2026 at 8:30 AM Eastern Time. Stockholders will vote on electing three Class II directors for three-year terms and ratifying Grant Thornton as independent registered public accounting firm for fiscal 2026.
The board has seven members, six of whom are independent, and is divided into three staggered classes. The proxy describes virtual-only access procedures, voting mechanics for record and beneficial holders, and quorum and vote standards. It also outlines 2025 executive pay, which combines base salary, cash incentives tied to revenue, EBITDA and debt prepayment, and equity awards in the form of restricted stock units and performance-based units tied to relative total shareholder return or stock price performance.
Airsculpt Technologies, Inc. major holder Jorey Chernett reported an open-market purchase of 20,000 shares of Common Stock at a weighted average price of $2.60 per share. After this transaction, he directly holds 7,013,761 shares of Airsculpt common stock.
Jashnani Yogesh reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. reported that Chief Executive Officer Yogesh Jashnani received a grant of 238,095 shares of Common Stock in the form of Restricted Stock Units on April 8, 2026 under the company’s 2021 Equity Incentive Plan. These RSUs will vest in three equal annual installments starting on April 8, 2027, contingent on his continued employment. Following this equity award, Jashnani directly holds 696,475 shares of Airsculpt common stock.
Arthur Michael J reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. reported that Chief Financial Officer Arthur Michael J received a grant of 68,027 shares of Common Stock as Restricted Stock Units on April 8, 2026 under the 2021 Equity Incentive Plan. The RSUs will vest in three equal annual installments beginning April 8, 2027, subject to his continued employment. Following this award, he directly holds 215,086 shares of common stock.